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Abstract  
 
Objective: To assess whether using surrogate versus patient-relevant endpoints in pivotal trials of cancer drugs 
was associated with HTA recommendations in England (National Institute for Health and Care Excellence - 
NICE) and Canada (Canadian Agency for Drugs and Technologies in Health - CADTH).  
 
Methods: Cancer drug approvals from 2012 to 2016 were categorised by demonstrating benefit on overall 
survival (OS), progression-free survival, disease response, or having no comparator. Approvals were analysed 
by benefit category and HTA recommendation. The association between benefit (surrogate versus OS) and 
recommending a drug was examined using descriptive statistics and linear probability models controlling for 
unmet need, orphan designation, and cost-effectiveness.   
 
Results: Of 42 cancer indications that NICE recommended, 15 (36%) demonstrated OS benefit. Cancer 
indications with OS benefit were less likely to receive a recommendation from NICE than those without 
(p=0.04). In linear probability models, availability of OS benefit was no longer associated with a 
recommendation from NICE (p=0.32). Cost-effective cancer drugs had a 55.6% [95% CI: 38.9% to 72.3%] 
higher probability of receiving a recommendation from NICE than those that were not. In Canada, 15 of 37 
(41%) cancer indications that were recommended showed OS benefit. There was no detectable association 
between surrogate measures and CADTH recommendations based on descriptive statistics (p=0.62) or in linear 
probability models (p=0.73).  
 
Conclusions: When cost-effectiveness was considered, pivotal trial endpoints were not associated with NICE 
recommendations. Pivotal trial endpoints, unmet need, orphan status, and cost-effectiveness did not explain 
CADTH recommendations.  
 
Key Words: surrogate outcomes, health technology assessment, cancer medicines 
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Highlights 
• Drug licensing agencies are under increasing pressure to expedite the approval of new cancer 
medicines. A common strategy to facilitate faster development of therapeutic agents is to use surrogate 
measures of clinical benefit. The validity of surrogates of overall survival in many cancer indications 
has been debated. There is no up to date study that evaluates the impact of surrogate measures on HTA 
recommendations.  
• This study shows no evidence that the use of surrogate measures in cancer trials are associated with a 
HTA decision to reject a drug. During our study period, cancer drugs without overall survival benefit 
were more likely to be recommended by NICE in England. However, when taking into consideration 
multiple factors, overall survival benefit did not affect NICE’s decisions, while cost-effectiveness 
did. CADTH decisions in Canada were not associated with the use of surrogate endpoints, unmet need, 
cost-effectiveness or orphan status.  
• These findings raise questions about the assumptions made in cost-effectiveness models in England, as 
multiple systematic reviews in oncology have found no clear relationship between surrogate measures 
and patient-centered outcomes, namely overall survival and quality-of-life.  
• The observed variation in CADTH decisions is not explained by known and measured factors in our 
analysis. Further clarity is needed on the framework guiding CADTH decisions on new cancer drugs.   
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Introduction  
Surrogate measures, such as progression-free survival (PFS), are substitutes to patient-relevant 
endpoints in cancer trials.
1
 Thus, changes seen in a surrogate endpoint are expected to emulate changes in a 
patient-relevant endpoint, such as overall survival (OS) or quality of life (QoL). Using surrogate measures in 
cancer trials have several benefits as they allow for shorter study durations, smaller sample sizes,
2
 lower costs 
and earlier approval of new drugs for cancer patients.
3,4
 In recent years, PFS and response rates have become 
increasingly popular surrogate measures used in cancer trials.
5  
However, evidence shows that such surrogate measures may be an unpredictable marker of OS
6
 and 
QoL benefit.
7
 A systematic review in 2018
5
 failed to find a significant association between PFS and QoL in 
cancer trials. Another review of trial-level meta-analyses in 2019
8
 showed a low to moderate correlation 
between surrogate measures and OS.  
Licensing agencies such as the European Medicines Agency (EMA) focus on a drug’s benefit-risk 
profile for granting marketing authorisations.
1,4
 However, Health Technology Assessment (HTA) bodies, such 
as the National Institute of Health and Care Excellence (NICE) in England and the Canadian Agency for Drugs 
and Technologies in Health (CADTH) in Canada, are concerned with long-term comparative clinical and cost-
effectiveness in addition to efficacy and safety. HTA decision making is a multidisciplinary process that 
includes many factors that may differ across individual agencies. While some contributing factors are difficult to 
ascertain, such as the extent of input from experts and patients, agencies have a set of explicit criteria to inform 
their decisions. For example, both CADTH
9 
and NICE
10
 consider unmet need, disease prevalence, and equity 
alongside data on the drug’s comparative efficacy, safety, and cost-effectiveness.
 
  
In addition, endpoints used in pivotal trials may influence HTA decisions. Indeed, HTA bodies have a 
clear preference for patient-relevant endpoints over surrogates.
1,11,12
 According to a study
13
 of 21 international 
HTA agencies, most organisations’ guidelines stated that a surrogate measure was acceptable only in 
exceptional situations, given its validity had been proven based on factors such as consistently strong statistical 
association and biological and pathophysiological plausibility. This was further reiterated in a study
14
 
highlighting that HTA agencies preferred systematic reviews to confirm the association between a surrogate and 
patient-relevant endpoint when making decisions about reimbursement. Despite these preferences, a study
15
 
exploring the use of surrogate measures in cost-effectiveness models within HTA agencies found that submitted 
reports often lacked this evidence, yielding uncertainty surrounding the surrogate measures.  
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The objective of this study was to assess whether the use of surrogate measures in pivotal trials of 
cancer drugs authorised by the EMA affected funding recommendations made by HTA bodies in England 
(NICE) and Canada (CADTH). These two countries share transparency in their appraisal processes as well as 
publically funded healthcare systems. 
 
 
Methods  
Two independent investigators used the EMA’s website to retrieve all marketing authorisations for 
human cancer drugs approved between 1
st
 January 2012 and 31
st
 December 2016. All drugs under ‘Cancer’ and 
its subcategories, such as ‘Neoplasms by site’, were explored. Drugs were eligible for review if they were 
indicated specifically for cancer treatment. Generic drugs, hybrid medicines, extensions for indications and 
other cancer types, and supportive cancer drugs were excluded. All European Public Assessment Reports 
(EPARs) for the included indications were systematically reviewed to identify and analyse pivotal studies. It 
was possible for one drug’s market authorisation to have more than one indication. A Microsoft Excel data 
extraction form was created to record study characteristics from all pivotal studies, including trial design, 
sample size, availability of control group, blinding and crossover procedures, participant characteristics, 
duration of follow-up, primary and secondary endpoints, and trial results.  
Two investigators then independently identified instances where these indications were considered in 
NICE and CADTH HTA reviews via their websites, up until November 2018. Figure 1 displays policy 
pathways and potential recommendations for cancer drug indications in England and Canada. A separate 
Microsoft Excel data extraction form was created to systematically review HTA documents for each cancer 
drug, which included the indication(s), document number, and recommendation. In instances where appraisals 
were resubmitted, the initial guidance was only used if the resubmitted appraisal was still in progress.  
Each HTA document was also assessed to see if the therapeutic indication fulfilled an unmet clinical 
need, was considered cost-effective, or had an orphan designation. These variables were the same as those 
considered in Dakin et. al’s study
16
 investigating the influence of multiple factors on NICE’s decision-making. 
Unmet need was determined by agencies, often with input from patient advocacy groups, and was reported 
under the “Current Practice” and “Limitations of Current Therapy” in NICE and CADTH appraisals, 
respectively. Cost-effectiveness was discussed under the “Committee Discussions” section of appraisals for 
NICE, with a threshold of £30,000 per quality-adjusted life year (QALY)
17
, and the “Economic Evaluation” 
section for CADTH, with no explicit threshold.
18,19
 Budget impact analyses were not included in the analysis as 
	 7 
it is not an explicit criterion for NICE, and CADTH considers it alongside cost-effectiveness analyses. A drug 
was classified as “orphan” if it targeted a disease with a prevalence 5 or less per 10,000 in the European Union.
 
 
Figure 1: Policy pathway and potential recommendations for cancer drug indications in England and 
Canada 
 
 
Two investigators then individually reviewed results of the pivotal trials (both primary and secondary 
endpoints) and categorised them into one of the following four groups: trials that demonstrated statistical 
significance in terms of (1) OS, (2) PFS, (3) disease response (DR) (e.g., response rate), and (4) those that 
showed no statistical evidence of benefit in comparative trials (i.e., trials with no comparator groups). Results 
were considered statistically significant if they met criteria set out in the ‘Statistical methods’ section of the 
pivotal study – typically a two-sided p-value with an alpha of 0.05. Consistent with previous studies
20
, single-
arm trials were considered to show no statistical significance as they did not compare the intervention against a 
placebo or alternative treatment. When an indication showed benefit in more than one category, it was 
hierarchically classified into the category of highest importance. OS benefit was considered the most persuasive 
outcome based on recent EMA guidelines on the evaluation of anticancer drugs,
21
 followed by PFS, DR, and 
lastly no statistical benefit.  
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Drug indications were then analysed according to both benefit categorisation and HTA 
recommendation from NICE and/or CADTH. Paired t-tests were used to compare the likelihood of HTA 
agencies recommending a drug between cancer indications with and without OS benefit at the time of EMA 
approval. Linear probability models were then used to compare the likelihood of recommending a drug based on 
OS benefit, unmet need, orphan designations, and cost-effectiveness. Lastly, disagreements in recommendations 
between NICE and CADTH for the same indication were narratively analysed. 
 
Results   
Cancer medicines approved by the EMA between 2012 and 2016 
The EMA approved 58 indications for 48 drugs between 2012 and 2016. Approved indications and 
respective pivotal study data can be found in the online-only supplementary table (S1). All pivotal studies had 
OS and DR related endpoints, primarily objective response-rate, as either a primary or secondary outcome.  All 
pivotal trials, except for four, reported PFS as either a primary or secondary outcome. Of 58 indications, 25 
(43%) demonstrated statistical evidence of OS benefit, 35 (60%) PFS benefit, and 39 (67%) DR benefit. 17 
(29%) of the 58 indications’ pivotal studies were single-arm trials. Based on the hierarchal classification of 
benefit, 25 (43%) of the 58 indications were categorised as exhibiting OS benefit, 14 (24%) PFS benefit, 2 (3%) 
DR benefit, and 17 (29%) no comparator. Table 1 displays EMA approved indications and their respective 
HTA recommendations. 
 
Table 1: EMA cancer medicines market authorisations from 2012 to 2016, categorised by benefit shown 
when authorised and NICE and CADTH guidance 
ACTIVE SUBSTANCE BENEFIT 
CATEGORY 
NICE GUIDANCE CADTH GUIDANCE 
Lenvatinib (2015): DTC OS Recommended 
(Optimised) 
Recommend if cost-effectiveness 
improved 
Necitumumab (2016): nSCLC OS Not recommended - 
Nintedanib (2014): nSCLC OS Recommended - 
irinotecan hydrochloride 
tihydrate (2016): PMA 
OS Not recommended Recommend if cost-effectiveness 
improved 
Ramucirumab (2014): 
combination; gastric 
OS Not recommended Recommend if cost-effectiveness 
improved 
Ramucirumab (2014): 
monotherapy; gastric 
OS Not recommended Not Recommended 
trifluridine/tipiracil (2016): 
CRC 
OS Recommended Not Recommended 
Regorafenib (2013): CRC OS Terminated appraisal Not recommended 
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ACTIVE SUBSTANCE BENEFIT 
CATEGORY 
NICE GUIDANCE CADTH GUIDANCE 
trastuzumab emtansine (2013): 
BC 
OS Recommended Recommend if cost-effectiveness 
improved 
Pertuzumab (2013): BC OS Recommended Recommend if cost-effectiveness 
improved 
Radium Ra223 dichloride 
(2013): PC 
OS Recommended 
(Optimised) 
- 
Enzalutamide (2013): PC OS Recommended Recommended 
Cobimetinib (2015): melanoma OS Not recommended Recommend (Optimised) if cost-
effectiveness improved 
Nivolumab (2015): melanoma OS Recommended Recommend (Optimised) if cost-
effectiveness improved  
Vemurafenib (2012): melanoma OS Recommended Recommended (Optimised) if cost-
effectiveness improved 
Olaratumab (2016): soft tissue 
sarcoma 
OS Recommended 
(CDF) 
Conditionally recommended if cost-
effectiveness improved 
Decitabine (2012): AML OS Terminated Appraisal - 
Pegaspargase (2016): ALL OS Recommended 
(Optimised) 
- 
Ibrutinib (2014): CLL OS Recommended Recommend if cost-effectiveness 
improved 
Idelalisib (2014): CLL; one 
prior therapy 
OS Recommended 
(Optimised) 
Recommend if cost-effectiveness 
improved 
Obinutuzumab (2014): CLL OS Recommended 
(Optimised) 
Recommended 
Elotuzumab (2016): MM OS In progress  - 
Carfilzomib (2015): MM OS Discontinued Recommend (Optimised) if cost-
effectiveness improved 
Pomalidomide (2013): MM OS Recommended 
(Optimised) 
Recommend if cost-effectiveness 
improved 
Aflibercept (2013): CRC OS Not Recommended Not Recommended 
Vandetanib (2012): MTC PFS In progress Recommend if cost-effectiveness 
improved 
Afatinib (2013): nSCLC PFS Recommended 
(Optimised) 
Recommended (Optimised) 
Olaparib (2014): EOFP PFS Recommended 
(Optimised) 
Recommend if cost-effectiveness 
improved 
Palbociclib (2016): BC; 
combination with AI 
PFS Recommended Recommend (Optimised) if cost-
effectiveness improved 
Palbociclib (2016): BC; 
combination with fulvest 
PFS Suspended In progress 
 Axitinib (2012): RCC PFS Recommended Recommended  
Pembrolizumab (2015): 
melanoma 
PFS Recommended 
(Optimised) 
Recommend (Optimised) if cost-
effectiveness improved 
Trametinib (2014): melanoma PFS Recommended 
(Optimised) 
Recommend if cost-effectiveness 
improved 
Dabrafenib (2013): melanoma PFS Recommended Recommend if cost-effectiveness 
improved 
Ixazomib (2016): MM PFS Recommended 
(Optimised and CDF)  
In progress 
Panobinostat (2015): MM PFS Recommended - 
Pixantrone (2012): nHBL PFS Recommended 
(Optimised) 
- 
Cabozantinib (2014): MTC PFS Recommended (CDF) - 
Idelalisib (2014): CLL; first-line PFS Recommended Recommend if cost-effectiveness 
improved 
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ACTIVE SUBSTANCE BENEFIT 
CATEGORY 
NICE GUIDANCE CADTH GUIDANCE 
Talimogene laherparepvec 
(2015): melanoma 
DR Recommended 
(Optimised) 
- 
Bosutinib (2013): CML DR Recommended Recommend if cost-effectiveness 
improved 
Osimertinib (2016): nSCLC Single-arm 
Trial 
Recommended 
(Optimised and CDF) 
Recommend if cost-effectiveness 
improved 
Ceritinib (2015): nSCLC Single-arm 
Trial 
Recommended Recommend if cost-effectiveness 
improved 
Crizotinib (2012): nSCLC Single-arm 
Trial 
Recommended Recommend if cost-effectiveness 
improved 
Sonidegib (2015): BCC Single-arm 
Trial 
- - 
Vismodegib (2013): BCC; 
metastatic 
Single-arm 
Trial 
Not Recommended Recommend if cost-effectiveness 
improved 
Vismodegib (2013): BCC; 
locally advanced 
Single-arm 
Trial 
Not Recommended Recommend if cost-effectiveness 
improved 
Ponatinib (2013): CML Single-arm 
Trial 
Recommended Recommend if cost-effectiveness 
improved 
Ponatinib (2013): ALL Single-arm 
Trial 
Recommended Recommend if cost-effectiveness 
improved 
Blinatumomab (2015): ALL Single-arm 
Trial 
Recommended Recommend if cost-effectiveness 
improved 
Ibrutinib (2014): MCL Single-arm 
Trial 
Recommended  
(Optimised) 
Recommend if cost-effectiveness 
improved 
Idelalisib (2014): FL Single-arm 
Trial 
In progress Not recommended  
Daratumumab (2016): MM Single-arm 
Trial 
Recommended 
(Optimised and CDF) 
Not recommended 
Brentuximab vedotin (2012): 
HL; post-ASCT 
Single-arm 
Trial 
Recommended 
 
Recommend if cost-effectiveness 
improved 
Brentuximab vedotin (2012): 
HL; non-ASCT candidates 
Single-arm 
Trial 
Recommended 
 
Not recommended 
Brentuximab vedotin (2012): 
sALCL 
Single-arm 
Trial 
Recommended 
(Optimised) 
Recommend if cost-effectiveness 
improved 
Venetoclax (2016): CLL; no 
17p deletion 
Single-arm 
Trial 
Recommended 
(CDF) 
Conditionally recommended if cost-
effectiveness improved 
 
Venetoclax (2016): CLL; with 
17p deletion 
Single-arm 
Trial 
Recommended 
(CDF) 
Not Recommended 
AI = Aromatase Inhibitor, ALL = Acute Lymphoblastic Leukaemia , AML = Acute Myeloid Leukaemia, ASCT = Autologous Stem Cell 
Transplant, BC = Breast Cancer, BCC = Basal Cell Carcinoma, CDF = Cancer Drug Fund, CLL = Chronic Lymphocytic Leukaemia, CML 
= Chronic Myeloid Leukaemia, CRC = Colorectal Cancer, DTC = Differentiated Thyroid Carcinoma, EOFP = Epithelial Ovarian, 
Fallopian Tube, or Primary Peritoneal Cancer, FL = Follicular Lymphoma, HL = Hodgkin Lymphoma, MCL = Mantle Cell Lymphoma, 
MM = Multiple Myeloma,  MTC = Medullary Thyroid Cancer,  nHBL = Non-Hodgkin B-Cell Lymphoma, nSCLC = Non-Small Cell Lung 
Cancer, PC = Prostate Cancer, PMA = Pancreatic Metastatic Adenocarcinoma, RCC = Renal Cell Carcinoma, sALCL = Systemic 
Anaplastic Large Cell Lymphoma 
 
NICE and CADTH recommendations 
Of 58 EMA-approved indications, 57 were subsequently reviewed by NICE: it recommended 45 (79%) 
indications - 17 of which had an “Optimised” recommendation and 7 under the Cancer Drugs Fund (CDF), did 
not recommend 8 (14%), was reviewing 3 (5%), terminated 2 appraisals, suspended 1, and discontinued 1 (7%). 
Specific NICE guidance for each indication can be found in the online-only supplementary table (S2).  
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CADTH provided guidance on 47 of the 58 indications approved by the EMA: it recommended 37 
(79%) - 1 of which was an “Optimised” recommendation, 25 of which were recommended if the cost-
effectiveness was improved, 6 that were “Optimised” and if cost-effectiveness was improved, and 2 of which 
were conditionally recommended. 8 (17%) indications were not recommended and 2 (4%) were in progress.  
Specific CADTH guidance for each indication can be found in the online-only supplementary table (S3), as well 
as a cross-tab of the number of indications by recommendation for both agencies (S4). Detailed reasons for not 
recommending indications for each agency can be found in supplementary tables 5 and 6. 
 
NICE and CADTH recommendations per benefit category 
Of the 25 indications based on OS benefit, 8 (32%) were recommended, followed by 6 (24%) 
recommended (optimised) and 6 (24%) not recommended by NICE; of the 14 based on PFS data 6 (43%) were 
recommended (optimised), followed by 5 (36%) recommended; the 2 based on DR data were recommended; of 
the 17 with no statistical benefit, 7 (41%) were recommended followed by 4 (24%) recommended (optimised) 
and 4 (24%) recommended (CDF) (Figure 2).  
Excluding drugs that were in progress, terminated, suspended, discontinued or not evaluated, NICE 
provided guidance for 50 indications. NICE recommended 15 of 21 (71%) indications that had OS benefit at the 
time of EMA approval, and 27 of 29 (93%) indications that were approved on the basis of surrogate measures 
(PFS, DR, and single-arm trial data). The difference in proportions was 22 percentage points (71% versus 93%, 
p=0.04). When unmet need, orphan designation, and cost-effectiveness were incorporated into a linear 
probability model, OS benefit was no longer a statistically significant predictor (p=0.32). Unmet need (p=0.38) 
and orphan designation (p=0.09) were also not statistically significant predictors. Cost-effectiveness was the 
only significant predictor (p=0.00), increasing a drug’s probability of NICE recommending it by 55.6% [95% CI 
= 38.9 to 72.3%].  
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Figure 2: NICE guidance for EMA cancer drug market authorisations from 2012 to 2016 
 
 
Of the 25 indications based on OS data for CADTH, 8 (32%) were recommended if the cost-
effectiveness was improved to an acceptable level, followed by 6 (24%) not evaluated; of the 14 based on PFS 
data, 5 (36%) were recommended contingent on cost-effectiveness being improved, followed by 3 (21%) not 
evaluated; of the two based on DR data, 1 (50%) was not evaluated and 1 (50%) was recommended if cost-
effectiveness improved; of the 17 with no statistical benefit, 11 (65%) were recommended if cost-effectiveness 
was improved, followed by 4 (24%) that were not recommended (Figure 3). Online-only supplementary data 
show the proportion of specific recommendations per benefit category for NICE and CADTH (S7).  
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Figure 3: CADTH guidance for EMA cancer drug market authorisations from 2012 to 2016 
 
Excluding drugs that were in progress or not evaluated, CADTH provided guidance for 45 indications. 
CADTH recommended 15 of 19 (79%) indications based on OS benefit, and 22 of 26 (85%) based on non-OS 
benefit. The difference in proportions was 6 percentage points (85% versus 79%, p=0.62). When unmet need, 
orphan designation, and cost-effectiveness were incorporated into a linear probability model, availability of OS 
was still not a statistically significant predictor (p=0.73). Unmet need (p=0.62), orphan designation (p=0.72) and 
cost-effectiveness (p=0.65) were also not statistically significant predictors for a drug being recommended by 
CADTH. Table 2 provides the complete results of the linear probability model for NICE and CADTH. 
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Table 2: NICE and CADTH Linear Probability Model for EMA Cancer Drug Market Authorisations 
from 2012 to 2016 
NICE and CADTH Linear Probability Model for Recommending EMA Cancer Drug 
Market Authorisations from 2012 to 2016 
NICE* 
 Probability P-value 95% Confidence Interval 
Overall Survival -7.91% 0.318 [-23.67, 7.85] 
Unmet Need 8.98% 0.381 [-11.45, 29.41] 
Orphan Designation 13.68% 0.086 [-2.01, 29.38] 
Cost-effectiveness 55.64% 0.000 [38.95, 72.33] 
CADTH** 
 Probability P-value 95% Confidence Interval 
Overall Survival -4.31% 0.733 [-29.69, 21.07] 
 
Unmet Need -13.48% 0.618 [-67.59, 40.63] 
Orphan Designation -4.70% 0.723 [-31.33, 21.92] 
 
Cost-effectiveness 13.56% 0.653 [-46.97, 74.09] 
*p-value associated with F-value (Probability > F) = 0.000. R2 = 56%. 
**p-value associated with F-value (Probability > F) = 0.8530. R2 = 3.2%. 
 
 Out of the 58 indications, 47 (81%) were evaluated by both NICE and CADTH. The HTA bodies 
disagreed on 9 (19%) indications, specifically with one agency recommending the drug while the other did not. 
For 5 of 9 (56%) indications that NICE did not recommend, NICE concluded that the incremental cost-
effectiveness ratio (ICER) was over the threshold, while CADTH recommended the drugs only if the cost-
effectiveness was improved. For 3 of 9 (33%) indications that NICE did not recommend, NICE had uncertainty 
about clinical benefit, whereas CADTH was satisfied with the evidence. When CADTH did not recommend a 
drug, the main reason for 3 of 9 (33%) indications was that CADTH had clinical and cost-effectiveness 
uncertainty, while NICE recommended it under the CDF to collect more data. 2 of 9 (22%) indications not 
recommended by CADTH were not cost-effective, while for NICE these drugs reached End-of-Life criteria and 
had a higher cost threshold. Supplementary table S8 lists the reasons for each HTA disagreement. 
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Discussion  
 This study identified 58 cancer indications that received EMA marketing authorisations between 2012 
and 2016. Of these, less than half were approved based on statistically significant OS benefit. NICE issued 
guidance on 50 of the 58 market authorisations. Of the 42 recommended drugs, less than half were based on OS 
benefit. During our study period, NICE was more likely to recommend drugs with non-OS benefit than OS 
benefit. However, when considering OS in conjunction with unmet need, orphan designation and cost-
effectiveness, there was no difference between the probability of drugs with and without OS benefit to be 
recommended. Instead, cost-effectiveness was a statistically significant factor, consistent with Dakin et. al’s
16
 
findings that cost-effectiveness was the most important predictor for a drug being recommended. CADTH 
issued guidance on 45 of the 58 EMA market authorisations. Only 3 indications were solely recommended, 
while 34 were recommended with stipulations such as cost-effectiveness being improved or optimising the 
original indication. On its own or when analysed with unmet need, orphan designation, and cost-effectiveness, 
availability of OS benefit did not effect the likelihood of CADTH recommending a drug. 
In absolute terms, NICE was more likely to recommend drugs based on surrogate benefit, specifically 
PFS, rather than OS. An in-depth review showed the main reasons for this being that crossover diminished OS 
benefit, studies were not powered for OS, results suggested improvement despite non-significance, and results 
of ongoing trials were still pending. However, from the results of the linear probability model, the single most 
important factor predicting a recommendation from NICE was cost-effectiveness, as the difference between 
drugs with OS benefit and those without became no longer statistically significant. These results raise questions 
about the assumptions made in cost-effectiveness models when extrapolating the findings of surrogate measures 
to long-term clinical improvements; many systematic reviews
5-7
 found no clear relationship between surrogate 
endpoints and OS or QoL.  
OS benefit did not increase the likelihood of CADTH recommending a drug, which is inconsistent with 
the literature
2,11,22
 that HTA bodies prefer endpoints that show direct clinical improvements.
 
A study by 
Kreeftmeijer et al.
23
 found that patient-relevant endpoints in cancer clinical trials were associated with a higher 
percentage of being recommended by European payers, specifically in France, Germany and the United 
Kingdom. However, the authors also found that statistical significance alone was insufficient, as reimbursement 
bodies also focused on clinically relevant differences.
23
 This aligns with our study results, as OS was not a 
significant predictor for a CADTH recommending a drug by itself or when accounting for unmet need, cost-
effectiveness or orphan designation. Previous literature
24
 found that differences in drug recommendations 
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between England and Canada may be less about clinical or economic evidence, but instead associated with 
agency-specific processes such as willingness to accept risk. More clarity on the framework guiding CADTH 
decisions on cancer drugs is warranted.  
 Eight indications were not recommended by NICE and eight by CADTH. Interestingly, 6 of  8 (75%) 
of the medicines that were not recommended by NICE demonstrated OS benefit. A common reason for not 
recommending these drugs was high ICERs, some being over £100,000 per QALY gained, exceeding NICE’s 
cost-effectiveness threshold of £30,000.
17
 This is consistent with a previous review published in 2007
25
, which 
found that most NICE rejections were for drugs exceeding this threshold. Our findings suggest that statistically 
significant OS benefit does not outweigh cost-effectiveness – an important factor to consider in a publicly 
funded healthcare system. Similarly, rejection recommendations by CADTH were all cost-ineffective. These 
findings for both agencies are supported by Lim et al.
26
, who found that countries financed by general taxation 
are more likely to reimburse drugs the lower their ICER is, whereas countries such as Germany solely focus on 
clinical evidence. Although half of the rejection recommendations by CADTH showed statistical OS benefit, the 
magnitude of benefit was modest. Recommendation disagreements between NICE and CADTH commonly had 
one agency not recommending an indication while the other put a stipulation on its recommendation. For 
example, when CADTH did not recommend a drug due to clinical uncertainty, NICE would recommend it under 
the CDF. Moreover, when NICE did not recommend a drug because the ICER was above its threshold, CADTH 
would recommend it only if the cost-effectiveness was improved to an acceptable level.  
 Of the 58 cancer indications approved by the EMA, NICE evaluated 57 (98%), while CADTH only 
evaluated 47 (81%). Discrepancies in this can be explained by the fact that the EMA is a European regulatory 
agency, to which NICE directly looks for market authorisations. CADTH was used as a comparison HTA 
agency as the healthcare systems are similar, but has its own regulatory agency – the Health Products and Food 
Branch of Health Canada. Further, a major difference between NICE and CADTH was how each categorised 
drugs they recommended. While NICE either recommended or optimised a recommendation, CADTH, in 
addition to these, recommended a drug contingent on its cost-effectiveness being improved to an acceptable 
level. Of the 58 indications, 31 (53%) fell under this category for CADTH, while only 3 (5%) indications were 
solely recommended. As CADTH has not publicly stated its threshold
18,19
, what they deem an acceptable level 
of cost-effectiveness is unknown. It is important to note that CADTH’s ‘Recommend if cost-effectiveness is 
improved’ guidance could potentially be a ‘Not recommended’ guidance from NICE, as their approval 
processes slightly differ. CADTH has an initial and final recommendation. After the initial recommendation, all 
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participatory stakeholders may comment on the guidance. Once a final recommendation is issued, a separate 
process involves the pan-Canadian Pharmaceutical Alliance supporting individual jurisdictions through 
negotiations to ensure value for publicly funded drug programs.
27
 Comparatively, NICE recommends that 
pharmaceutical companies offer patient access schemes at the time of submission. A review of guidance that 
rejects a drug may occur if there is a discount in price (manufacturers can engage in confidential negotiations), 
but this would result in a new appraisal that reviews the initial decision.
28
 Further, differing appeal processes 
may account for variations between NICE
29
 and CADTH.
30
 
When analysing NICE’s approval process it is important to consider the Cancer Drug Fund (CDF) – a 
source of funding for cancer drugs in England that provides faster access to new treatments. From its inception 
in 2011 to 2016, the CDF reviewed treatments not yet appraised or considered too rare for appraisal by NICE, 
not recommended by NICE, or not licensed for the proposed clinical purpose.
31
 There has been criticism that 
NICE strategically did not recommend drugs knowing that the CDF would fund them instead. However, the 
CDF was restructured in 2016 to operate under NICE.
32
 Presently, for the CDF to consider a drug, NICE must 
first recommend it for use within the CDF. This recommendation means the drug has potential to be eligible to 
be recommended by NICE, but has remaining clinical, and thus cost-effectiveness, uncertainty.
32
 The drug then 
enters a managed access period to resolve any significant remaining clinical uncertainty.
32
 This paper’s analysis 
of NICE’s recommendations was completed both before and after the CDF’s restructuring. Thus, there is the 
possibility that NICE strategically did not recommend certain indications with the expectation that the CDF 
would for some products in our sample. 
 This study has limitations. Firstly, EMA-approved drugs were analysed so that comparisons could be 
made between England and Canada based on one list of drugs, despite Canada having its own regulatory body. 
Secondly, we relied exclusively on publicly available information. We were unable to consider the extent of 
expert or patient contribution to decision-making, as these were difficult to accurately quantify from public 
reports. Also, it remains a possibility that individual factors and their relative contribution to HTA decisions 
may have evolved over our study period. Fourthly, this study defined benefit as statistical significance in a 
comparative trial. Thus, single-arm trials were categorised as having no statistical evidence of benefit, even 
when they demonstrated improvement in terms of surrogate measures.
 
Our focus on statistically significant 
findings may over-simplify the complex HTA decision-making process, which also considers aspects beyond 
the type of endpoint that showed statistical benefit. HTA agencies also consider factors such as standard of care 
available, therapeutic area, and political factors
16
, for example the relationship between the CDF and NICE. 
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Furthermore, clinically meaningful benefit is becoming increasingly important in oncology, with organisations 
such as ESMO
33
 and ASCO
34
 developing frameworks to evaluate it.
 
These were not assessed as they are 
currently not used by NICE and CADTH, but do provide important information on value in cancer care. Of 
note, drugs with OS benefit do score higher under the ESMO framework than those without.
33
 Despite many 
factors influencing the decision-making process, surrogate measures still pose a substantial challenge to HTA 
bodies due to uncertainty surrounding their correlation to clinical outcomes.   
 While drug licensing agencies increasingly rely on surrogate measures to grant marketing 
authorisation, HTA bodies have traditionally preferred patient-relevant endpoints.
12,15
 In practice, HTA bodies 
must make decisions on licensed products even when desirable evidence is unavailable. Our results show that 
statistically significant benefit from a patient-relevant endpoint does not always confirm a HTA 
recommendation. Further, surrogate measures are becoming increasingly context-specific
2
 with diverse patient 
populations and the emergence of new technologies
 
and mechanisms of actions.
35
 This makes evidence of 
surrogate validity from retrospective trials harder to apply to different contexts. Current surrogate measures used 
in cancer research do not show consistently strong associations with OS. HTA agencies must ensure that 
surrogate measures amount to meaningful benefit. One solution would be to capitalise on conditional 
reimbursements
25,36
, which stipulate that drugs need to prove clinical benefit within a certain time frame after 
reimbursement. 
 
Conclusion 
 The use of surrogate measures in cancer trials was not associated with a HTA decision to reject a drug 
in England and Canada. NICE was less likely to recommend cancer drugs with OS benefit compared to those 
with PFS or DR. However, when also considering unmet need, orphan designation and cost-effectiveness, OS 
was not statistically significantly associated with a drug being recommended. Instead, this was driven by cost-
effectiveness. This finding raises questions about the assumptions made in cost-effectiveness models in 
England, as multiple systematic reviews have demonstrated an unclear relationship between PFS and OS or 
QoL. Pivotal trial endpoints, unmet need, orphan status, and cost-effectiveness did not significantly affect 
CADTH recommendations during our study period. Further clarity is needed on the factors guiding 
recommendations of cancer drugs in Canada to ensure accountability.  
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